AE37: A novel T-cell-eliciting vaccine for breast cancer

Alan K. Sears, Sonia A. Perez, Guy T. Clifton, Linda C. Benavides, Jeremy D. Gates, Kevin S. Clive, Jarrod P. Holmes, Nathan M. Shumway, David C. Van Echo, Mark G. Carmichael, Sathibalan Ponniah, Constantin N. Baxevanis, Elizabeth A. Mittendorf, Michael Papamichail, George E. Peoples*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

42 Scopus citations

Abstract

Introduction: Immunotherapy, including vaccines targeting the human EGFR2 (HER-2/neu) protein, is an active area of investigation in combatting breast cancer. Several vaccines are currently undergoing clinical trials, most of which are CD8 + T-cell-eliciting vaccines. AE37 is a promising primarily CD4 + T-cell-eliciting HER-2/neu breast cancer vaccine currently in clinical trials. Areas covered: This article reviews preclinical investigations as well as findings from completed and ongoing Phase I and Phase II clinical trials of the AE37 vaccine. Expert opinion: Clinical trials have shown the AE37 vaccine to be safe and capable of generating peptide-specific, durable immune responses. This has been shown in patients with any level of HER-2/neu expression. Early clinical findings suggest there may be benefit to AE37 vaccination in preventing breast cancer recurrence.

Original languageEnglish
Pages (from-to)1543-1550
Number of pages8
JournalExpert Opinion on Biological Therapy
Volume11
Issue number11
DOIs
StatePublished - Nov 2011
Externally publishedYes

Keywords

  • AE36 peptide
  • AE37 vaccine
  • Breast cancer
  • Cancer vaccines
  • Ii-Key hybrid
  • Prostate cancer

Fingerprint

Dive into the research topics of 'AE37: A novel T-cell-eliciting vaccine for breast cancer'. Together they form a unique fingerprint.

Cite this